Literature DB >> 8917180

Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism.

D R Neumann1, C B Esselstyn, W J Maclntyre, R T Go, N A Obuchowski, E Q Chen, A A Licata.   

Abstract

UNLABELLED: Preoperative localization of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism has been a longstanding diagnostic challenge. This study directly compared FDG-PET and sestamibi-SPECT for preoperative detection of abnormal parathyroid tissue.
METHODS: Twenty-one consecutive patients with primary hyperparathyroidism were studied prospectively before surgical neck exploration. SPECT of the neck and chest was performed at 15 min and 2 hr after intravenous 99mTc-sestamibi. Regional body PET was performed 45 min after intravenous FDG.
RESULTS: Surgery revealed 19 solitary parathyroid adenomas, 2 parathyroid adenomas in one patient; and 3 hyperplastic parathyroid glands in one patient, and 51 normal parathyroid glands. The diagnostic sensitivities for detection of parathyroid adenomas of 43% (9 of 21) for dual-phase sestamibi-SPECT and 86% (18 of 21) for FDG-PET were significantly different (p < 0.001). The difference in diagnostic specificities of 78% (40 of 51) for FDG-PET and 90% (46 of 51) for dual-phase sestamibi-SPECT approached statistical significance (p = 0.063).
CONCLUSION: This study demonstrates that FDG-PET is more sensitive than sestamibi-SPECT in the preoperative localization of parathyroid adenomas in patients with primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8917180

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  FDG PET/CT findings in primary hyperparathyroidism mimicking multiple bone metastases.

Authors:  Hakan Demir; Metin Halac; Gozde D Gorur; Kerim Sonmezoglu; Ilhami Uslu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-11       Impact factor: 9.236

2.  ¹⁸F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study.

Authors:  Luka Lezaic; Sebastijan Rep; Mojca Jensterle Sever; Tomaz Kocjan; Marko Hocevar; Jure Fettich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-26       Impact factor: 9.236

Review 3.  Imaging for primary hyperparathyroidism--an evidence-based analysis.

Authors:  Radu Mihai; Dietmar Simon; Per Hellman
Journal:  Langenbecks Arch Surg       Date:  2009-07-10       Impact factor: 3.445

4.  Power and sample size requirements for non-inferiority in studies comparing two matched proportions where the events are correlated.

Authors:  Jun-Mo Nam
Journal:  Comput Stat Data Anal       Date:  2011-10-01       Impact factor: 1.681

5.  Diagnostic performance of positron emission tomography using ¹¹C-methionine in patients with suspected parathyroid adenoma: a meta-analysis.

Authors:  Carmelo Caldarella; Giorgio Treglia; Maria Antonietta Isgrò; Alessandro Giordano
Journal:  Endocrine       Date:  2012-07-18       Impact factor: 3.633

6.  Comparison of hyperparathyroidism types and utility of dual radiopharmaceutical acquisition with Tc99m sestamibi and 123I for localization of rapid washout parathyroid adenomas.

Authors:  Y S Kushchayeva; S H Tella; S V Kushchayev; D Van Nostrand; K Kulkarni
Journal:  Osteoporos Int       Date:  2019-01-31       Impact factor: 4.507

7.  Non-inferiority tests for clustered matched-pair data.

Authors:  Jun-Mo Nam; Deukwoo Kwon
Journal:  Stat Med       Date:  2009-05-30       Impact factor: 2.373

Review 8.  Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management.

Authors:  M Naji; M Hodolic; S El-Refai; S Khan; M C Marzola; D Rubello; A Al-Nahhas
Journal:  J Endocrinol Invest       Date:  2009-10-09       Impact factor: 4.256

9.  Primary hyperparathyroidism: retrospective 10-year study of 32 cases.

Authors:  Sumit Shukla; Manish Kaushal; Satish K Shukla
Journal:  Indian J Surg       Date:  2008-09-16       Impact factor: 0.656

10.  2009 EANM parathyroid guidelines.

Authors:  Elif Hindié; Omer Ugur; David Fuster; Michael O'Doherty; Gaia Grassetto; Pablo Ureña; Andrew Kettle; Seza A Gulec; Francesca Pons; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.